


Searching News Database: alcohol dependence
HSMN NewsFeed - 30 Aug 2023
Alkermes Announces Settlement With Teva Related to VIVITROL(R) Patent Litigation
Alkermes Announces Settlement With Teva Related to VIVITROL(R) Patent Litigation
HSMN NewsFeed - 17 Mar 2016
Elite Announces U.S. FDA Priority Review Designation for SequestOx(TM) NDA
Elite Announces U.S. FDA Priority Review Designation for SequestOx(TM) NDA
HSMN NewsFeed - 6 Feb 2013
Elite Pharmaceuticals Announces FDA Approval of Supplemental Application for Naltrexone
Elite Pharmaceuticals Announces FDA Approval of Supplemental Application for Naltrexone
HSMN NewsFeed - 4 Aug 2008
Alkermes Announces Approval of VIVITROL(R) for the Treatment of Alcohol Dependence in Russia
Alkermes Announces Approval of VIVITROL(R) for the Treatment of Alcohol Dependence in Russia
HSMN NewsFeed - 7 Mar 2008
Alkermes Receives Notice from Eli Lilly Terminating Inhaled Insulin Program
Alkermes Receives Notice from Eli Lilly Terminating Inhaled Insulin Program
HSMN NewsFeed - 27 Feb 2008
Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
HSMN NewsFeed - 7 Jan 2008
Alkermes Announces Agreement for the Commercialization of VIVITROL in Russia/CIS
Alkermes Announces Agreement for the Commercialization of VIVITROL in Russia/CIS
HSMN NewsFeed - 18 Dec 2007
Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
HSMN NewsFeed - 2 Dec 2007
FDA Issues Approvable Letter for Nebivolol for the Treatment of Hypertension
FDA Issues Approvable Letter for Nebivolol for the Treatment of Hypertension
HSMN NewsFeed - 17 Sep 2007
Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration
Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration
HSMN NewsFeed - 5 Sep 2007
Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
HSMN NewsFeed - 21 Aug 2007
Daiichi Sankyo and Forest Laboratories Sign Letter of Intent for Co-Promotion of AZOR(TM)
Daiichi Sankyo and Forest Laboratories Sign Letter of Intent for Co-Promotion of AZOR(TM)
HSMN NewsFeed - 22 Jun 2007
TransOral Pharmaceuticals, Inc. Changes Name to Transcept Pharmaceuticals, Inc.
TransOral Pharmaceuticals, Inc. Changes Name to Transcept Pharmaceuticals, Inc.
HSMN NewsFeed - 1 May 2007
Response Submitted to FDA Approvable Letter for Hypertension Compound Nebivolol
Response Submitted to FDA Approvable Letter for Hypertension Compound Nebivolol
HSMN NewsFeed - 25 Apr 2007
Alkermes and Indevus Announce Initiation of Phase 2a Clinical Study of ALKS 27 for the Treatment of COPD
Alkermes and Indevus Announce Initiation of Phase 2a Clinical Study of ALKS 27 for the Treatment of COPD
HSMN NewsFeed - 13 Apr 2007
FDA Approves New Dose of RISPERDAL(R) CONSTA(R) for Schizophrenia Treatment
FDA Approves New Dose of RISPERDAL(R) CONSTA(R) for Schizophrenia Treatment
HSMN NewsFeed - 20 Dec 2006
Alkermes Announces Submission of New Drug Application for RISPERDAL(R) CONSTA(R) in Japan
Alkermes Announces Submission of New Drug Application for RISPERDAL(R) CONSTA(R) in Japan
HSMN NewsFeed - 14 Dec 2006
Cerexa to Be Acquired by Forest Laboratories for $480 Million Plus Potential $100 Million Milestone Payment
Cerexa to Be Acquired by Forest Laboratories for $480 Million Plus Potential $100 Million Milestone Payment
HSMN NewsFeed - 23 Oct 2006
U.S. Food and Drug Administration Issues Non-Approvable Letter for Faropenem
U.S. Food and Drug Administration Issues Non-Approvable Letter for Faropenem
Additional items found! 39
Members Archive contains
39 additional stories matching:
alcohol dependence
(Password required)
alcohol dependence
(Password required)
